Christopher F. Mojcik is SVP Clinical Development at ALEXION PHARMACEUTICALS INC (ALXN). They have made 3 open-market trades across 1 company since 2007, most recently 2007-05-29.
CIK 0001231951
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases totalling $237K since 2007, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALXN | 111,605 | $20.4M |
Shares reported on the most recent Form 4, priced at the 2007-05-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALXN | BUY | 2007-05-29 | 2007-05-31 | $47.11 | $237K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2007-05-29 | 2007-05-31 | $47.79 | $503K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2007-05-29 | 2007-05-31 | $47.22 | $2.8M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2007-05-29 | 2007-05-31 | $47.07 | $1.4M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL · 10b5-1 | 2007-03-12 | 2007-03-14 | $37.15 | $21K | -15.6% | -1.2% | -1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.